3-Year Follow-Up of the Balloon Elution and Late Loss Optimization Study (BELLO).

[1]  R. Whitbourn,et al.  Dynamics of vessel wall changes following the implantation of the absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months. , 2014, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[2]  M. Spiecker,et al.  Prospective ‘real world’ registry for the use of the ‘PCB only’ strategy in small vessel de novo lesions , 2013, Heart.

[3]  P. Serruys,et al.  Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial. , 2013, JACC. Cardiovascular interventions.

[4]  H. Ackermann,et al.  Treatment of small coronary arteries with a paclitaxel-coated balloon catheter in the PEPCAD I study: are lesions clinically stable from 12 to 36 months? , 2013, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[5]  A. Lansky,et al.  Drug eluting balloons for de novo coronary lesions – a systematic review and meta-analysis , 2013, BMC Medicine.

[6]  A. Colombo,et al.  A randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels: the BELLO (Balloon Elution and Late Loss Optimization) study. , 2012, Journal of the American College of Cardiology.

[7]  Patrick W Serruys,et al.  A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial , 2008, The Lancet.

[8]  A. Kastrati,et al.  Predictive Factors of Restenosis After Coronary Implantation of Sirolimus- or Paclitaxel-Eluting Stents , 2006, Circulation.